Sign In
Buy CGEM
$16.50
-1.02 (-5.82%)
At Close: Jul 31, 2026
Phase 3 trial will assess progression-free survival of zipalertinib plus chemotherapy versus chemotherapy in adult patients with previously untreated, locally advanced or metastatic non-squamous non
Cullinan Oncology to Participate in Upcoming Investor Conferences
08:00am, Monday, 31'st Jul 2023
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapie
Why Shares of Cullinan Oncology Jumped This Week
04:07pm, Friday, 09'th Jun 2023
Cullinan Oncology's lead therapy is zipalertinib, which is in a trial to treat non-small cell lung cancer. The company has a deep pipeline and published encouraging news regarding preclinical candidat
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
05:00pm, Thursday, 25'th May 2023
CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced tha
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial clinical data from the ongoing trial is on-track t
Cullinan Oncology to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 01'st Nov 2022
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology for pati
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
06:16am, Thursday, 22'nd Sep 2022
Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after.
Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
02:45pm, Wednesday, 14'th Sep 2022
Cullinan Oncology's total cash and short-term investment is $611 million, up 94% from the previous quarter. The company's portfolio consists of eight product candidates that can significantly improve
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
08:00am, Wednesday, 07'th Sep 2022
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of target
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
08:00am, Thursday, 19'th May 2022
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapie
Why Are Cullinan Oncology Shares Rising Today?
11:34am, Thursday, 12'th May 2022
Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417. Under the agreement, Taiho will acquire Cullinan Oncology's subs
Cullinan Oncology to Present at the Barclays Global Healthcare Conference
08:00am, Wednesday, 09'th Mar 2022
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted ther
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
05:30pm, Tuesday, 08'th Mar 2022
Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare Conference
06:30am, Monday, 07'th Feb 2022
CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink's 11th Annual Global Healthcare
